ArticleFuture oncology (London, England)2025
Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe incidence and mortality rates of breast cancer are increasing globally every year. Paclitaxel is one of the most widely used chemotherapeutic agents for solid tumors. Conducting studies in the real world is of great clinical importance and research value. This study evaluates the application and efficacy of different types of paclitaxel in patients with advanced breast cancer.
methodsA retrospective cohort study was conducted. For effectiveness, we focused on objective response rate (ORR), Disease Control Rate (DCR), and progression-free survival (PFS). For safety, we focused on the incidence of adverse events (ARE). The Kaplan-Meier survival function, and COX proportional risk regression model were used for data processing and analysis.
resultsNab-paclitaxel DCR was significantly higher than paclitaxel liposome (
conclusionNab-paclitaxel or paclitaxel liposomes remain significantly effective in patients with advanced breast cancer who have failed first or multiline therapy. Nab-paclitaxel is superior to paclitaxel liposome in efficacy evaluation, paclitaxel liposome is superior to nab-paclitaxel in survival outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.